Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
August 28 2023 - 7:00AM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that members of its senior management
will participate in a fireside chat at the H.C. Wainwright 25th
Annual Global Investment Conference on Monday, September 11, 2023
at 9:30am Eastern Time.
A live webcast of the event will be available on the 'Events
& Presentations' section of Xeris’ Investor Relations website
at https://xerispharma.com/investor-relations or
https://journey.ct.events/view/773cc0a3-0963-44b6-8523-1d257c8286d0
A replay of the webcast will be available for 60 days.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™, to support long-term product development and commercial
success.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230828934661/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2024 to May 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From May 2023 to May 2024